Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(11):825; doi:10.1093/jnci/djk225
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Correction (v99,p1054)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Classification of NSCLC Patients for EGFR Inhibitor Benefits

Only a subset of patients with non–small-cell lung cancer (NSCLC) respond to gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR), but a larger fraction appear to have prolonged stabilization of disease. Taguchi et al. (p. 838) investigated whether mass spectrometic features in pretreatment blood serum might be used to classify NSCLC patients according to their outcomes after treatment with these drugs. To do so, they developed a matrix-assisted laser desorption/ionization (MALDI) algorithm from a training set of patients with known outcomes. They tested the algorithm on two independent validation cohorts. In . . . [Full Text of this Article]

Comparing Cisplatin, Carboplatin for Treatment of Advanced NSCLC

Proteomic Signature and Outcome in Patients with NSCLC

Integrin {alpha}7 Mutations and Various Types of Human Cancers

Aspirin, Nonaspirin NSAIDs, and Cancer Incidence and Mortality

Inflammation, C-Reactive Protein, and Breast Cancer Risk

Incidence of Intra- and Extrahepatic Cholangiocarcinoma in Denmark


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap?
Ming-Sound Tsao, Geoffrey Liu, and Frances A. Shepherd
J Natl Cancer Inst 2007 99: 826-827. [Extract] [Full Text] [PDF]

Cisplatin Versus Carboplatin for Patients With Metastatic Non–Small-Cell Lung Cancer—An Old Rivalry Renewed
Christopher G. Azzoli, Mark G. Kris, and David G. Pfister
J Natl Cancer Inst 2007 99: 828-829. [Extract] [Full Text] [PDF]

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, Heinrich Roder, Robert Gray, Kazuo Kasahara, Makoto Nishio, Julie Brahmer, Anna Spreafico, Vienna Ludovini, Pierre P. Massion, Rafal Dziadziuszko, Joan Schiller, Julia Grigorieva, Maxim Tsypin, Stephen W. Hunsucker, Richard Caprioli, Mark W. Duncan, Fred R. Hirsch, Paul A. Bunn, Jr, and David P. Carbone
J Natl Cancer Inst 2007 99: 838-846. [Abstract] [Full Text] [PDF]

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljevic, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, Donald Bisset, and Rafael Rosell
J Natl Cancer Inst 2007 99: 847-857. [Abstract] [Full Text] [PDF]

A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non–Small-Cell Lung Cancer
Kiyoshi Yanagisawa, Shuta Tomida, Yukako Shimada, Yasushi Yatabe, Tetsuya Mitsudomi, and Takashi Takahashi
J Natl Cancer Inst 2007 99: 858-867. [Abstract] [Full Text] [PDF]

Analysis of Integrin {alpha}7 Mutations in Prostate Cancer, Liver Cancer, Glioblastoma Multiforme, and Leiomyosarcoma
Baoguo Ren, Yan P. Yu, George C. Tseng, Chuanyue Wu, Ka Chen, Uma N. Rao, Joel Nelson, George K. Michalopoulos, and Jian-Hua Luo
J Natl Cancer Inst 2007 99: 868-880. [Abstract] [Full Text] [PDF]

Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality
Aditya Bardia, Jon O. Ebbert, Robert A. Vierkant, Paul J. Limburg, Kristin Anderson, Alice H. Wang, Janet E. Olson, Celine M. Vachon, and James R. Cerhan
J Natl Cancer Inst 2007 99: 881-889. [Abstract] [Full Text] [PDF]

C-Reactive Protein and Risk of Breast Cancer
Shumin M. Zhang, Jennifer Lin, Nancy R. Cook, I-Min Lee, JoAnn E. Manson, Julie E. Buring, and Paul M. Ridker
J Natl Cancer Inst 2007 99: 890-894. [Abstract] [Full Text] [PDF]

Incidence Rates of Intra- and Extrahepatic Cholangiocarcinomas in Denmark From 1978 Through 2002
Peter Jepsen, Hendrik Vilstrup, Robert E. Tarone, Søren Friis, and Henrik Toft Sørensen
J Natl Cancer Inst 2007 99: 895-897. [Abstract] [Full Text] [PDF]

Erratum
J Natl Cancer Inst 2007 99: 1054. [Extract] [Full Text] [PDF]